AC-101

Accro Bioscience (Suzhou) Limited · Phase 1 active Small molecule

At a glance

Generic name	AC-101
Sponsor	Accro Bioscience (Suzhou) Limited
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study of AC-101 Tablets in Participants With Moderate to Severe Active Ulcerative Colitis (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

AC-101 CI brief — competitive landscape report
AC-101 updates RSS · CI watch RSS
Accro Bioscience (Suzhou) Limited portfolio CI